Display options
Cite
Honkanen EA, Eklund M, Nuuttila S, et al. Dopamine transporter binding in symptomatic controls and healthy volunteers: Considerations for neuroimaging trials. Neuroimage Clin. 2021;32:102807doi: 10.1016/j.nicl.2021.102807.
Honkanen, E. A., Eklund, M., Nuuttila, S., Noponen, T., Jaakkola, E., Mäkinen, E., Hirvilammi, R., Seppänen, M., Lindholm, K., Scheperjans, F., Parkkola, R., Joutsa, J., Varrone, A., & Kaasinen, V. (2021). Dopamine transporter binding in symptomatic controls and healthy volunteers: Considerations for neuroimaging trials. NeuroImage. Clinical, 32102807. https://doi.org/10.1016/j.nicl.2021.102807
Honkanen, Emma A, et al. "Dopamine transporter binding in symptomatic controls and healthy volunteers: Considerations for neuroimaging trials." NeuroImage. Clinical vol. 32 (2021): 102807. doi: https://doi.org/10.1016/j.nicl.2021.102807
Honkanen EA, Eklund M, Nuuttila S, Noponen T, Jaakkola E, Mäkinen E, Hirvilammi R, Seppänen M, Lindholm K, Scheperjans F, Parkkola R, Joutsa J, Varrone A, Kaasinen V. Dopamine transporter binding in symptomatic controls and healthy volunteers: Considerations for neuroimaging trials. Neuroimage Clin. 2021 Aug 30;32:102807. doi: 10.1016/j.nicl.2021.102807. Epub 2021 Aug 30. PMID: 34482280; PMCID: PMC8416950.
Copy Download .nbib Format: NLM
Share it on

Neuroimage Clin. 2021 Aug 30;32:102807. doi: 10.1016/j.nicl.2021.102807. Epub 2021 Aug 30.

Dopamine transporter binding in symptomatic controls and healthy volunteers: Considerations for neuroimaging trials.

NeuroImage. Clinical

Emma A Honkanen, Mikael Eklund, Simo Nuuttila, Tommi Noponen, Elina Jaakkola, Elina Mäkinen, Risto Hirvilammi, Marko Seppänen, Kari Lindholm, Filip Scheperjans, Riitta Parkkola, Juho Joutsa, Andrea Varrone, Valtteri Kaasinen

Affiliations

  1. Clinical Neurosciences, University of Turku and Turku University Hospital, Turku, Finland; Department of Neurology, Satasairaala Central Hospital, Pori, Finland; Turku PET Centre, Turku University Hospital, Turku, Finland. Electronic address: [email protected].
  2. Clinical Neurosciences, University of Turku and Turku University Hospital, Turku, Finland; Turku PET Centre, Turku University Hospital, Turku, Finland.
  3. Clinical Neurosciences, University of Turku and Turku University Hospital, Turku, Finland.
  4. Department of Clinical Physiology and Nuclear Medicine, University of Turku and Turku University Hospital, Turku, Finland; Department of Medical Physics, Turku University Hospital, Turku, Finland.
  5. Department of Clinical Physiology and Nuclear Medicine, University of Turku and Turku University Hospital, Turku, Finland.
  6. Department of Neurology, Helsinki University Hospital and Department of Clinical Neurosciences (Neurology), University of Helsinki, Helsinki, Finland.
  7. Department of Radiology, University of Turku and Turku University Hospital, Turku, Finland.
  8. Clinical Neurosciences, University of Turku and Turku University Hospital, Turku, Finland; Turku PET Centre, Turku University Hospital, Turku, Finland; Turku Brain and Mind Center, University of Turku, Turku, Finland.
  9. Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm Health Care Services, Stockholm, Sweden.

PMID: 34482280 PMCID: PMC8416950 DOI: 10.1016/j.nicl.2021.102807

Abstract

OBJECTIVE: To evaluate possible differences between brain dopamine transporter (DAT) binding in a group of symptomatic parkinsonism patients without dopaminergic degeneration and healthy individuals.

BACKGROUND: Dopaminergic neuroimaging studies of Parkinson's disease (PD) have often used control groups formed from symptomatic patients with apparently normal striatal dopamine function. We sought to investigate whether symptomatic patients can be used to represent dopaminergically normal healthy controls.

METHODS: Forty healthy elderly individuals were scanned with DAT [

RESULTS: DAT binding in symptomatic patients was 8.6% higher in the posterior putamen than in healthy controls (p = 0.03). Binding correlated negatively with age in both groups but not with motor symptom severity, cognitive function or depression ratings.

CONCLUSIONS: Putaminal DAT binding, as measured with [

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Keywords: Controls; Dopamine transporter; Healthy controls; SPECT

Publication Types